Table 1.
Summary statistics at questionnaire cycle of entry into ARAMIS
| Variable | Never on Prednisone | Ever on Prednisone | Overall |
|---|---|---|---|
| 38% (N=2130) | 62% (N=3496) | (N=5626) | |
| Age | 57.3+/−14.3 | 56.9+/−13.5 | 57.1+/−13.8 |
| Gender | |||
| Male | 26% ( 553) | 24% ( 834) | 25% (1387) |
| Ethnicity | |||
| Non-white | 11% ( 224) | 10% ( 357) | 10% ( 581) |
| Education level in years | 12.61+/− 2.76 | 12.75+/− 2.58 | 12.70+/− 2.65 |
| Disease duration | 10.54+/−10.60 | 10.61+/−10.05 | 10.58+/−10.26 |
| BMI | 26.50+/− 5.17 | 26.52+/− 5.30 | 26.51+/− 5.25 |
| Rheumatology consult | |||
| Yes | 63% (1352) | 73% (2569) | 70% (3921) |
| HAQ-DI score | 0.976+/−0.762 | 1.234+/−0.779 | 1.136+/−0.782 |
| Pain score | 1.119+/−0.774 | 1.333+/−0.781 | 1.252+/−0.785 |
| Mean duration of observation | 5.67+/− 5.56 | 7.46+/− 6.04 | 6.78+/− 5.93 |
| Hypertension | 18% ( 387) | 21% ( 732) | 20% (1119) |
| Coronary disease | 2% ( 53) | 4% ( 145) | 4% ( 198) |
| Lung disease | 8% ( 180) | 12% ( 410) | 10% ( 590) |
| Intestinal disease | 11% ( 235) | 17% ( 595) | 15% ( 830) |
| Liver disease | 1% ( 15) | 1% ( 33) | 1% ( 48) |
| Diabetes mellitus | 4% ( 92) | 4% ( 135) | 4% ( 227) |
| Cancer | 4% ( 75) | 4% ( 129) | 4% ( 204) |
| Congestive heart failure | 0% ( 10) | 1% ( 34) | 1% ( 44) |
| Stroke | 1% ( 20) | 1% ( 36) | 1% ( 56) |
| Infections | 4% ( 93) | 13% ( 451) | 10% ( 544) |
| Mean no. of comorbidities | 0.915+/−1.288 | 1.260+/−1.432 | 1.129+/−1.389 |
| Prednisone | 0% ( 0) | 64% (2245) | 40% (2245) |
| MTX | 20% ( 436) | 32% (1113) | 28% (1549) |
| Sulfasalazine | 3% ( 59) | 4% ( 155) | 4% ( 214) |
| Other DMARDs* | 32% ( 682) | 46% (1595) | 40% (2277) |
| TNF inhibitors | 2% ( 39) | 2% ( 66) | 2% ( 105) |
| NSAIDs | 62% (1331) | 65% (2273) | 64% (3604) |
| COX2 inhibitors | 2% ( 53) | 2% (86) | 2% ( 139) |
*
excluding methotrexate and sulfasalazine